I guess you liked the T-shirts?

For Babies Sake, Make Cronobacter sakazakii Reportable

According to the AP:

U.S. health officials will start formally tracking infections caused by the rare but potentially deadly germ that sickened babies and triggered a nationwide shortage of infant formula last year.

A group that advises the Centers for Disease Control

According to press reports, the U.S. Food and Drug Administration said on Wednesday it was notified of one more infant death in January potentially related to Abbott Laboratories’ baby formula and the agency has started a probe.

Abbott initiated a recall of its infant formula products and closed its Michigan plant in February after reports

According to the CDC and FDA, at least 4 kids were sickened and of those two died, from drinking Abbott infant formula.  Abbott denies the connection.  However, the resulting investigation and inspection (and whistleblower documents) uncovered enough problems in the Abbott facility to shutter it causing havoc with supplies of infant formula.  The facility is

Here are the highlights of the Consent Decree:

  • Abbott has agreed to take corrective actions following an FDA inspection of its Sturgis, Michigan facility
  • Abbott Nutrition will be required to retain an independent expert to review the Sturgis facility’s operations to ensure compliance with the law.
  • It also includes requirements for testing products, as

This week the CDC declared an outbreak of Cronobacter infections over after the FDA received four complaints of Cronobacter infections in infants beginning on September 20, 2021, through January 11, 2022. Two of the babies died. Parents of all four infants reported having fed their children formula produced by Abbott Nutrition before they became ill.

Thank goodness for Rosa.

House Appropriations Committee Chair Rosa DeLauro (D-CT-03) today submitted for the record a report acquired from a whistleblower who worked at the Abbott facility which produces infant formula recalled by the United States Food and Drug Administration (FDA) in February. Chair DeLauro spoke about the report at the Fiscal Year 2023